Research Topics
| G M FelkerSummaryAffiliation: Duke University Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Inotropic therapy for heart failure: an evidence-based approachG M Felker
Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
Am Heart J 142:393-401. 2001..Despite this fact, inotropes remain commonly used in the management of heart failure...
A standardized definition of ischemic cardiomyopathy for use in clinical researchG Michael Felker
Duke Clinical Research Institute, Durham, North Carolina, USA
J Am Coll Cardiol 39:210-8. 2002....
Validation and potential mechanisms of red cell distribution width as a prognostic marker in heart failureLarry A Allen
Division of Cardiology, University of Colorado Denver, Aurora, CO, USA
J Card Fail 16:230-8. 2010..Our study sought to validate the prognostic value of RDW in heart failure and to explore the potential mechanisms underlying this association...
Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher riskThomas P Cappola
Department of Medicine, Division of Cardiology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
Circulation 105:1663-8. 2002..These findings suggest that secondary pulmonary hypertension may have different biological features in myocarditis and that patients with pulmonary hypertension and myocarditis should be targeted for aggressive medical therapy...
Racial differences in the characteristics of patients admitted for acute decompensated heart failure and their relation to outcomes: results from the OPTIME-CHF trialMelvin R Echols
Duke Clinical Research Institute, Durham, North Carolina 27705, USA
J Card Fail 12:684-8. 2006..Although unadjusted clinical outcomes are better for African Americans presenting with ADHF, these differences diminished after adjustment for baseline characteristics...
Marginal cardiac allografts do not have increased primary graft dysfunction in alternate list transplantationBrian Lima
DUMC Box 3043, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
Circulation 114:I27-32. 2006..Pre-transplant VAD and prolonged ischemic times are more important determinants of PGD. These data support continued aggressive utilization of marginal donor hearts in AL HT...
Natriuretic peptides in the diagnosis and management of heart failureG Michael Felker
Outcomes Research Group, Duke Clinical Research Institute, and the Division of Cardiology and Department of Medicine, Duke University Medical Center, Durham, NC 27705, USA
CMAJ 175:611-7. 2006....
Troponin elevation in heart failure prevalence, mechanisms, and clinical implicationsRobb D Kociol
Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
J Am Coll Cardiol 56:1071-8. 2010..Ultimately, this information might allow physicians to guide therapy, choose appropriate therapeutics, and improve HF outcomes...
Advances in the surgical treatment of heart failureLarry A Allen
Division of Cardiovascular Medicine, Duke University Medical Center, Durham, North Carolina, USA
Curr Opin Cardiol 23:249-53. 2008..The purpose of this review is to discuss emerging surgical therapies in heart failure, in particular, mechanical cardiac support and mitral valve repair...
Risk stratification after hospitalization for decompensated heart failureG Michael Felker
Duke Clinical Research Institute, 2400 Pratt Street, Room 0311, Terrace Level, Durham, NC 27705, USA
J Card Fail 10:460-6. 2004..Further research into the validity of this model in independent samples will potentially aid in the development of risk stratification strategies...
The Valsalva maneuver: a bedside "biomarker" for heart failureG Michael Felker
Duke Clinical Research Institute, Durham, NC 27715, USA
Am J Med 119:117-22. 2006..Although often overlooked in clinical training and practice, the cardiovascular response to the Valsalva maneuver is a potentially useful, noninvasive means of evaluating filling pressures in patients with heart failure...
Implantable left ventricular assist devices: new hope for patients with end-stage heart failureCarmelo A Milano
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
N C Med J 67:110-5. 2006..Recently, the Food and Drug Administration approved implantable left ventricular assist devices (LVAD) as destination therapy (DT) for end-stage heart failure patients who are ineligible for cardiac transplantation...
Anemia in patients with heart failure and preserved systolic functionG Michael Felker
Duke Clinical Research Institute, Durham, NC 27705, USA
Am Heart J 151:457-62. 2006..Although heart failure in the setting of preserved systolic function (PSF) is an important clinical problem, the relationship between anemia and outcomes in patients with PSF has not been carefully evaluated...
Same bridge, new destinations rethinking paradigms for mechanical cardiac support in heart failureG Michael Felker
Duke University School of Medicine, Durham, North Carolina 27705, USA
J Am Coll Cardiol 47:930-2. 2006....
The African-American heart failure trial: a new look at old drugsG Michael Felker
Duke Clinical Research Institute, 2400 Pratt St, Room 0311 Terrace Level, Durham, NC 27705, USA
Future Cardiol 1:311-3. 2005..Future research will be required to assess whether benefits of this drug combination seen in AHeFT can be extended to the wider population of patients with advanced heart failure...
N-terminal pro-brain natriuretic peptide and exercise capacity in chronic heart failure: data from the Heart Failure and a Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) studyG Michael Felker
Duke Clinical Research Institute, Durham, NC 27705, USA
Am Heart J 158:S37-44. 2009..To examine the relationship between N-terminal pro-brain natriuretic peptide (NT-proBNP) and exercise capacity in a large contemporary cohort of patients with chronic heart failure...
A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatmentLynda A Szczech
Renal Division, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
Kidney Int 77:239-46. 2010..These differential outcomes underscore the need for dedicated trials in these subpopulations...
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke DatabankG Michael Felker
Duke Clinical Research Institute, Durham, North Carolina, USA
J Am Coll Cardiol 50:40-7. 2007..The goal of this study was to identify potentially novel laboratory markers of risk in chronic heart failure patients...
The pathophysiology of acute heart failure--is it all about fluid accumulation?Gad Cotter
Duke University Medical Center, The Duke Clinical Research Institute, Durham, NC 27715, USA
Am Heart J 155:9-18. 2008....
Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trialsG Michael Felker
Duke Clinical Research Institute and the Division of Cardiology, Duke University Medical Center, Durham, NC 27705, USA
Am Heart J 158:422-30. 2009..We performed a quantitative meta-analysis of available randomized controlled trials to determine whether titration of therapy based on natriuretic peptide measurements improves mortality in chronic heart failure...
Early worsening heart failure in patients admitted with acute heart failure--a new outcome measure associated with long-term prognosis?Beth Davison Weatherley
Momentum Research Inc, Durham, NC, USA
Fundam Clin Pharmacol 23:633-9. 2009..7-6.3). Early WHF is a common adverse event in patients admitted with AHF, and is associated with AHF severity and excessive 6-month mortality. WHF should be considered as a clinically important endpoint in AHF studies...
The problem of decompensated heart failure: nomenclature, classification, and risk stratificationG Michael Felker
Duke Clinical Research Institute, Durham, NC 27705, USA
Am Heart J 145:S18-25. 2003..It also defines the current understanding of strategies for risk stratification in the setting of decompensated heart failure...
Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failureBenjamin H Trichon
Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
Am J Cardiol 91:538-43. 2003..MR is common in patients with LV systolic dysfunction and heart failure. After adjusting for other clinical variables, the presence of MR independently predicted worsened survival...
Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failureWendy A Gattis
Duke University Medical Center Duke Clinical Research Institute, Division of Cardiology, Durham, North Carolina 27705, USA
Am J Cardiol 91:169-74. 2003..These results also suggest that caution should be taken when withdrawing beta blockade in this population...
Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF studyG Michael Felker
Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
J Am Coll Cardiol 41:997-1003. 2003..The goal of this study was to assess the interaction between heart failure (HF) etiology and response to milrinone in decompensated HF...
Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failureG Michael Felker
Duke Clinical Research Institute, Durham, North Carolina 27715, USA
Am J Cardiol 92:625-8. 2003..Lower baseline hemoglobin is associated with risk of short-term adverse clinical outcomes in this population, even after controlling for other baseline differences...
Survival after coronary revascularization, with and without mitral valve surgery, in patients with ischemic mitral regurgitationBenjamin H Trichon
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
Circulation 108:II103-10. 2003....
Diuretic strategies in patients with acute decompensated heart failureG Michael Felker
Duke University School of Medicine and Duke Heart Center, Durham, NC, USA
N Engl J Med 364:797-805. 2011..Loop diuretics are an essential component of therapy for patients with acute decompensated heart failure, but there are few prospective data to guide their use...
Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failureKaren E Joynt
Department of Medicine Division of Cardiology, Duke University Medical Center, Durham, North Carolina 27710, USA
Am J Cardiol 93:783-5. 2004..Baseline angiotensin-converting enzyme inhibitor plus beta-blocker use were associated with lower levels of CRP; no relation was found between CRP levels and aspirin or statin use...
United States stock market performance and acute myocardial infarction rates in 2008-2009 (from the Duke Databank for Cardiovascular Disease)Mona Fiuzat
Division of Cardiology, Duke University Medical Center, Durham, North Carolina, USA
Am J Cardiol 106:1545-9. 2010..02). In conclusion, unadjusted and adjusted analyses of patients in the Duke Databank for Cardiovascular Disease indicated a significant correlation between a period of stock market decrease and increased AMI rates in our local cohort...
Outcomes with an alternate list strategy for heart transplantationG Michael Felker
Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA
J Heart Lung Transplant 24:1781-6. 2005..The creation of an alternate list to match recipients with contraindications to traditional HT with sub-optimal donor organs has been implemented at some centers, but outcomes using this approach are uncertain...
Anaemia and coronary artery disease severity in patients with heart failureG Michael Felker
Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA
Eur J Heart Fail 8:54-7. 2006..Exacerbation of myocardial ischemia in patients with heart failure, coronary disease, and anaemia patients has been suggested as a potential mechanism underlying this association...
Anemia as a risk factor and therapeutic target in heart failureG Michael Felker
Duke Clinical Research Institute, Durham, North Carolina 27715, USA
J Am Coll Cardiol 44:959-66. 2004..Multiple ongoing studies will provide definitive data on the balance of risks and benefits of anemia treatment in chronic HF...
Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) TrialSunil V Rao
Duke Clinical Research Institute, Durham, NC, USA
Circulation 121:1713-21. 2010..We performed a phase 2 randomized trial to evaluate the safety and feasibility of M118 in the setting of elective percutaneous coronary intervention...
Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) programLarry A Allen
Division of Cardiology, University of Colorado Denver, Aurora, CO, USA
Eur J Heart Fail 11:170-7. 2009..The prevalence and importance of liver function test (LFT) abnormalities in a large contemporary cohort of heart failure patients have not been systematically evaluated...
Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of measures of disease severity in acutLarry A Allen
Division of Cardiology, University of Colorado Denver, Aurora, CO 80045, USA
J Card Fail 14:777-84. 2008..The natural evolution of signs and symptoms during acute heart failure (AHF) is poorly characterized...
End points for clinical trials in acute heart failure syndromesLarry A Allen
Division of Cardiology, Department of Medicine, University of Colorado Denver, Aurora, CO 80045, USA
J Am Coll Cardiol 53:2248-58. 2009....
Inflammatory biomarkers in heart failureJohn W Petersen
Division of Cardiovascular Medicine, Duke University Medical Center, Durham, NC, USA
Congest Heart Fail 12:324-8. 2006..In this review, the authors analyze available data supporting the use of inflammatory markers both as biomarkers and as potential therapeutic targets...
Inotropes in the management of acute heart failureJohn W Petersen
Division of Cardiovascular Medicine, Duke University Medical Center, Durham, NC, USA
Crit Care Med 36:S106-11. 2008..Whether newer inotropes with differing mechanisms of action will realize the potential clinical benefits of inotropic therapy without the risk remains a subject of ongoing investigation...
Infectious complications in extended criteria heart transplantationKeshava Rajagopal
Department of Surgery, Division of Thoracic Surgery, Duke University Medical Center, Durham, North Carolina, USA
J Heart Lung Transplant 27:1217-21. 2008..We hypothesized that other adverse outcomes, principally determined by recipient characteristics, occur at a higher rate in extended criteria recipients...
Effect of nesiritide in patients with acute decompensated heart failureC M O'Connor
Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27710, USA
N Engl J Med 365:32-43. 2011..Nesiritide is approved in the United States for early relief of dyspnea in patients with acute heart failure. Previous meta-analyses have raised questions regarding renal toxicity and the mortality associated with this agent...
Rapid clinical assessment of patients with acute heart failure: first blood pressure and oxygen saturation--is that all we need?Olga Milo-Cotter
Momentum Research Inc, 3100 Tower Blvd, Suite 802, Durham, NC 27707, USA
Cardiology 114:75-82. 2009..Low oxygen saturation (SaO2) and systolic blood pressure (SBP) are signs of impending respiratory and circulatory failure that can be obtained quickly in patients with AHF...
Impact of left ventricular assist device bridging on posttransplant outcomesJay D Pal
Division of Thoracic Surgery, Duke University Medical Center, Durham, North Carolina 27705, USA
Ann Thorac Surg 88:1457-61; discussion 1461. 2009..However, referral for LVAD therapy may be limited secondary to reports of poor outcomes when mechanical circulatory support is required before transplantation...
Relationship between anemia and health care costs in heart failureLarry A Allen
Division of Cardiology, University of Colorado Denver, Aurora, Colorado 80045, USA
J Card Fail 15:843-9. 2009..Anemia is associated with higher morbidity and mortality in patients with heart failure (HF), but its implications for heath care costs are not well described...
Discordance between patient-predicted and model-predicted life expectancy among ambulatory patients with heart failureLarry A Allen
Duke Clinical Research Institute and Division of Cardiology, Durham, NC 27705, USA
JAMA 299:2533-42. 2008..Patients with chronic heart failure have impaired long-term survival, but their own expectations regarding prognosis have not been well studied...
Mortality in primary and secondary myocarditisTodd C Pulerwitz
Cardiology Division, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA
Am Heart J 147:746-50. 2004..Lymphocytic myocarditis presents as a primary disorder or in association with a systemic disease. Whether primary and secondary myocarditis have the same prognosis is unknown...
Recurrence of cardiac sarcoidosis in a heart transplant recipientJonathan E E Yager
Division of Cardiology, Duke University Medical Center, Durham, North Carolina, USA
J Heart Lung Transplant 24:1988-90. 2005..He subsequently underwent uncomplicated heart transplantation. Nineteen months later, a routine surveillance endomyocardial biopsy specimen demonstrated recurrence of sarcoidosis in the transplanted heart...
Left ventricular assist devices as destination therapy for end-stage heart failureJonathan E E Yager
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
Am Heart J 148:252-3. 2004
Rational use of inotropic therapy in heart failureG M Felker
Division of Cardiology, Department of Medicine, Duke University Medical Center, DUMC Box 3356, Durham, NC 27710, USA
Curr Cardiol Rep 3:108-13. 2001..An understanding of the appropriate goals of therapy is important for both patients and physicians if rational decisions about the use of inotropes are to be made...
A global ranking approach to end points in trials of mechanical circulatory support devicesG Michael Felker
Duke Clinical Research Institute, Durham, NC 27705, USA
J Card Fail 14:368-72. 2008..The ideal composite end point for studies of MCSDs is uncertain...
Topical anesthesia with EMLA reduces pain during endomyocardial biopsy: a randomized trialDianne H Leloudis
Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina
J Heart Lung Transplant 25:1164-6. 2006..A better understanding of the factors affecting pain during EMBx could improve the comfort level of this procedure...
Hyponatraemia in acute heart failure is a marker of increased mortality but not when associated with hyperglycaemiaOlga Milo-Cotter
Momentum Research, Inc, Durham, NC 27707, USA
Eur J Heart Fail 10:196-200. 2008..Although diabetes is a common co-morbidity in heart failure, no prior study has considered the impact of serum glucose on this relationship...
Acute heart failure associated with high admission blood pressure--a distinct vascular disorder?Olga Milo-Cotter
Duke University Medical Center and the Duke Clinical Research Institute, Durham NC, 27515, USA
Eur J Heart Fail 9:178-83. 2007..Although blood pressure (BP) is elevated in patients with acute heart failure (AHF), first admission BP has not been meticulously recorded before treatment in previous studies...
The impact of arrhythmias in acute heart failureRaymond L Benza
University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
J Card Fail 10:279-84. 2004..CONCLUSION: New arrhythmia during an exacerbation of heart failure identifies a high-risk group with higher intrahospital and 60-day morbidity and mortality...
Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) sLiviu Klein
Northwestern University Feinberg School of Medicine, Chicago, Ill 60611, USA
Circulation 111:2454-60. 2005..CONCLUSIONS: In patients hospitalized for worsening heart failure, admission serum sodium is an independent predictor of increased number of days hospitalized for cardiovascular causes and increased mortality within 60 days of discharge...
Unraveling the pathophysiology of acute heart failure: an inflammatory proposalG Michael Felker
Am Heart J 151:765-7. 2006
A bridge for the 21st century in heart transplantation?G Michael Felker
Am Heart J 145:198-9. 2003
B-type natriuretic peptide - a biomarker for all seasons?Daniel B Mark
N Engl J Med 350:718-20. 2004
